I agree that very little value or no value for cancer has been realized in the share price. Other than a short spike to $.58 this stock hasn’t moved much over the past few months even with several positive PRs. That seems a little crazy as other biotechs jump 100s of percent in a day based on positive results in early trials.

IMO as long as the science/leronlimab continue to display positive results the ‘slight risk’ of any negative outcome with this stock/my investment is zilch. Although the way the share price reacts to positive news, I wouldn’t be the least bit shocked if mediocre or bad cancer results sunk it significantly.....I 100% believe we will have positive results, just saying that is what I would expect even though the share price has not realized any value for said cancer potential.